DRI Capital

DRI Capital is a Canadian private investment firm specializing in pharmaceutical and biotechnology royalty streams. The firm focuses on acquiring existing royalty streams and revenue interests derived from products in the life sciences industry from inventors, academic and research institutions, or companies. DRI Capital manages two funds: the Royalty Monetization Fund and the Structured Finance Fund. The Royalty Monetization Fund acquires existing royalty streams at competitive rates, while the Structured Finance Fund provides non-dilutive financing for product acquisitions, launches, mergers and acquisitions, in-licensing, sales force expansion, and general working capital purposes to companies within the healthcare industry. DRI Capital has been instrumental in creating a robust and liquid market for the recipients of royalties on healthcare-related products. Over the years, the firm has completed numerous royalty transactions and purchased royalty entitlements, holding a diversified portfolio of healthcare royalty entitlements. The company's investment strategy aims to provide risk-mitigated exposure across multiple therapeutic areas, generating attractive returns and sustainable growth for stakeholders. DRI Capital's track record includes significant investments in leading pharmaceutical products, contributing to the advancement of medical treatments and innovations in the healthcare sector.

Established pharmaceutical or biotechnology companies with existing royalty streams, Innovative products with strong market potential, Opportunities for non-dilutive financing in the healthcare industry, Companies seeking capital for product acquisitions, launches, or general working capital purposes